Computer-aided detection gains popularity for use in screening and diagnostic mammography

Share this article:

Radiologists have increased their use of computer-aided detection (CAD) in screening and diagnostic mammography, according to a study published in the Journal of the American College of Radiology (2010 Oct;7(10):802-5).

For the study, researchers at Thomas Jefferson University Hospital reviewed codes in records from 2004 to 2008 for screening and diagnostic mammography, as well as screening and diagnostic CAD.

The results of the study revealed that in 2008, of the screening mammograms performed, 74% involved the use of CAD, compared to 39% in 2004. “By 2008, CAD was used in about three-quarters of all screening exams and half of all diagnostic exams,” said Vijay Rao, MD, lead author of the study. “The use of CAD is controversial, while some support it and others are critical of it. Nonetheless, while there remains debate over the efficacy of CAD, it is apparent that radiologists are increasingly utilizing this technology and that it is becoming standard practice in breast diagnosis." ONA

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Early promise against melanoma from new antibody-drug conjugate

The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.

Aging is sped up in breast cancer survivors who underwent adjuvant chemotherapy

Adjuvant chemotherapy for breast cancer is gerontogenic, defined as accelerating the pace of physiologic aging, a new study reported.

Subset of patients with breast cancer patients will most likely benefit from ...

The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for HR-negative, HER2-positive primary (nonmetastatic) breast cancer patients.